Dr. Neelima Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, discusses the results of the MONARCH-2 study presented here at ASCO.  The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib+fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant.